This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Valeant Readies Hostile Exchange Offer for Allergan

NEW YORK (The Deal) -- Canada's Valeant Pharmaceuticals International (VRX - Get Report) on Tuesday said it plans to launch an exchange offer later this week to put its $54 billion hostile bid to acquire Allergan (AGN - Get Report) before shareholders, as part of a broader effort to step up its effort to acquire the California-based drug maker best known as the maker of Botox.

The expedited effort comes after Allergan, based in Irvine, Calif., last week rejected Valeant Pharmaceutical's latest raised, unsolicited offer. That bid is backed by activist Bill Ackman's hedge fund, Pershing Square Capital Management LP, which set up a joint venture with Valeant and owns most of a 9.7% stake in the target.

The exchange offer can't be consummated unless the company removes its 10% poison pill. However, even if it fails -- as expected -- an exchange offer is a good way to gauge investor sentiment for a deal.

"We have a clear path to completion of a transaction; we will be patient since time is on our side," Valeant said in a Tuesday presentation. "We believe that shareholders should have the opportunity to express their views, and we are confident that both Allergan and Valeant shareholders will support this combination."

Valeant and Pershing had indicated previously that an exchange offer was in the works. However, more details were provided Tuesday.

At the same time as Valeant tries for shareholder support for its hostile exchange offer, Pershing will be seeking consents to call a special shareholder meeting for investors to vote on removing a majority of Allergan's board.

Ackman needs an additional 15.3% of votes to call a meeting, which is unlikely to be held until November.

If he gets the necessary consents for a meeting, investors will also vote on a nonbinding proposal to install a slate of six Ackman-backed nominees.

Shareholder approval of the unsolicited exchange offer and a vote to remove incumbent Allergan directors would make it clear that not only do shareholders want to remove a majority of the company's board but they also want it to be sold at a specific price, people familiar with the situation said.

Both efforts could put enough public pressure on Allergan that it agrees to a Valeant tie-up.

If Ackman is successful at removing the majority of the board, and Allergan doesn't subsequently agree to negotiate with Valeant, he plans on petitioning the Delaware Chancery Court to hold another special election - that would be for a traditional proxy contest pitting Ackman's candidates against Allergan's incumbents.

The hedge fund manager might also shift to a strategy to remove the entire Allergan board. If successful, it could spur Delaware Chancery Court to move faster because a judge wouldn't want the company to continue on a rudderless course without a board of directors.

Allergan has been putting up a fight to remain independent, including saying that Valeant's business model, which includes numerous acquisitions, is "unsustainable." In a statement Monday, Allergan released a list of hedge fund managers, biotech experts and analysts critiquing Valeant's M&A schedule.

Allergan went so far in the Monday statement as to release an e-mail from Morgan Stanley from when the bank was pitching itself as an adviser to the company.

In the e-mail, healthcare banker David Horn noted that the bank's M&A chief Robert Kindler could use "his significant relationships with media and analysts to provide a clear and detailed articulation of why Valeant is a house of cards and your investors should not want to take their stock."

Subsequently, Valeant hired Morgan Stanley as its financial adviser.

A Morgan Stanley spokeswoman declined to comment.

Valeant sought to respond Tuesday, releasing a series of quotes from analysts who argued that a Valeant-Allergan deal is compelling and that its operating model is "durable and sustainable."

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AGN $218.85 0.00%
VRX $35.25 0.00%
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs